Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE42376 | PF PRISM CV | Substituted 3-cyanoquinolines |
Apr, 2024
(1 year, 2 months from now) | |
US7767678 | PF PRISM CV | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
Nov, 2026
(3 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7417148 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(2 years from now) | |
US7919625 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(2 years from now) | |
US11103497 | PF PRISM CV | Treatment of imatinib resistant leukemia |
Feb, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 19, 2024 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
Market Authorisation Date: 04 September, 2012
Treatment: A method of treating chronic myelogenous leukemia; A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at 949t>c; A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at f317l
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6890927 | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May, 2022
(8 months ago) | |
US7265119 | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Aug, 2022
(6 months ago) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6890927
(Pediatric) | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Nov, 2022
(2 months ago) | |
US7265119
(Pediatric) | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Feb, 2023
(13 hours from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Feb 22, 2022 |
Pediatric Exclusivity (PED) | Aug 22, 2022 |
Drugs and Companies using VARENICLINE TARTRATE ingredient
Market Authorisation Date: 10 May, 2006
Treatment: Aid to smoking cessation
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6534524 | PF PRISM CV | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Apr, 2025
(2 years from now) | |
US8791140 | PF PRISM CV | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals |
Dec, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10570202 | PF PRISM CV | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
Feb, 2035
(12 years from now) | |
US10869924 | PF PRISM CV | PD-L1 antagonist combination treatments |
Jan, 2037
(13 years from now) |
Drugs and Companies using AXITINIB ingredient
Market Authorisation Date: 27 January, 2012
Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6673838 | PF PRISM CV | Succinate salt of O-desmethyl-venlafaxine |
Mar, 2022
(11 months ago) | |
US8269040 | PF PRISM CV | Derivatives of venlafaxine and methods of preparing and using the same |
Jul, 2027
(4 years from now) |
Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient
Market Authorisation Date: 29 February, 2008
Treatment: For the approved uses and conditions of use, including depression; Maintenance treatment of major depressive disorder (mdd)
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8455539 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(5 months from now) | |
US8299116 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(5 months from now) | |
US8722700 | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jul, 2023
(5 months from now) | |
US8299116
(Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(11 months from now) | |
US8722700
(Pediatric) | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jan, 2024
(11 months from now) | |
US8455539
(Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(11 months from now) | |
US8026276 | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jan, 2026
(2 years from now) | |
US8026276
(Pediatric) | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jul, 2026
(3 years from now) | |
US8791097 | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
May, 2032
(9 years from now) | |
US8791097
(Pediatric) | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
Nov, 2032
(9 years from now) |
Drugs and Companies using TEMSIROLIMUS ingredient
Market Authorisation Date: 30 May, 2007
Treatment: Method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; Method of treating metastatic papillary renal cell carcinoma with temsirolimus.
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9694078 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(3 years from now) | |
US10588975 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(3 years from now) | |
US9254328 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(3 years from now) | |
US8975242 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Oct, 2028
(5 years from now) | |
US7879828 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Feb, 2029
(6 years from now) | |
US8372995 | PF PRISM CV | Crystalline solid forms of tigecycline and methods of preparing same |
Oct, 2030
(7 years from now) |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 15 June, 2005
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8785632 | PF PRISM CV | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
Mar, 2025
(2 years from now) | |
US7230098 | PF PRISM CV | Aminoheteroaryl compounds as protein kinase inhibitors |
Aug, 2025
(2 years from now) | |
US7858643 | PF PRISM CV | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
Oct, 2029
(6 years from now) | |
US8217057 | PF PRISM CV | Polymorphs of a c-MET/HGFR inhibitor |
Nov, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7825137 | PF PRISM CV | Method of treating abnormal cell growth |
May, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jan 14, 2028 |
New Indication (I) | Jul 14, 2025 |
Drugs and Companies using CRIZOTINIB ingredient
Market Authorisation Date: 26 August, 2011
Treatment: Treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (alcl) that is anaplastic lymphoma kinase (alk)-positive; Treatment of patients with metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6965027 | PF PRISM CV | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(a month from now) | |
USRE41783 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(2 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Dec 14, 2024 |
New Patient Population (NPP) | Sep 25, 2023 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
Market Authorisation Date: 06 November, 2012
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6984403 | PF PRISM CV | Azithromycin dosage forms with reduced side effects |
Feb, 2024
(1 year, 11 days from now) | |
US7887844 | PF PRISM CV | Multiparticulate crystalline drug compositions having controlled release profiles |
Feb, 2024
(1 year, 11 days from now) |
Drugs and Companies using AZITHROMYCIN ingredient
Market Authorisation Date: 10 June, 2005
Treatment: Method of treating bacterial infections
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic